ACAD vs HIMS
ACADIA Pharmaceuticals Inc. vs Hims & Hers Health — AI-powered side-by-side comparison
ACAD
ACADIA Pharmaceuticals Inc.
61
Buy
VS
HIMS
Hims & Hers Health
52
Watch
| Metric | ACAD | HIMS |
|---|
| AI Score |
61
|
52
|
| Price |
$29.68
|
$29.88
|
| P/E Ratio |
13.59×
|
-52.05×
|
| ROE |
31.9%
|
23.7%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
91.1%
|
64.7%
|
| Debt / Equity |
0.06×
|
4.77×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
69.3
|
55.0
|
| Beta |
0.845
|
2.415
|
| Expected Upside |
—
|
+0.3%
|
AI Committee View
Current Innellis committee reasoning for ACAD versus HIMS.
ACAD leads by 9 points.
ACAD scores 61/100 (Buy) versus HIMS at 52/100 (Watch).
ACAD Committee View
60% agreement
5 analysts
The committee is genuinely divided. Growth Analyst sees a compelling case — quarter-over-quarter growth rate is accelerating, not just positive. Risk Analyst remains cautious — bollinger bandwidth of 21.2% signals elevated volatility. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
Bear Case
- MACD histogram negative -- bearish momentum — Technical
- Weekly RSI at 75 -- overbought on the larger timeframe too — Technical
- Bollinger bandwidth of 21.2% signals elevated volatility — Risk
HIMS Committee View
50% agreement
6 analysts
The committee is genuinely divided. Macro Analyst sees a compelling case. Value Analyst remains cautious — price-to-book of 13.7x prices in significant intangible value. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- Revenue growing 32.8% YoY -- genuine top-line momentum — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- Price-to-book of 13.7x prices in significant intangible value — Value
- ROE of only -2.5% -- cheap may mean cheap for a reason — Value
- Debt-to-equity of 1.80 adds balance-sheet risk to the value case — Value